Toddler Skin Patch Immunotherapy for Peanut Allergy

Exciting news for peanut allergy reduction in young children. DVB

Technologies is working on a skin patch for children under 4 years of age

and a recent study showed promising results in reaction reduction to the

allergen peanut. Thanks to Snack Safely for sharing!

Emerging TherapyNews CoverageStudy

Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut Allergy

ByDave Bloom

-2022/11/17 269

Viaskin Patch

Fact: there are currently no approved peanut allergy treatments for children younger than four years old.

Research presented at this year’s American College of Allergy, Asthma & Immunology (ACAAI) 2022 annual meeting shows that children 1-3 years old with peanut allergy who received epicutaneous immunotherapy showed a statistically significant response to treatment.

Epicutaneous immunotherapy (EPIT) exposes tolerance-promoting immune cells in the skin to a dermal patch containing a tiny dose of a food protein. DBV Technologies is pioneering work in EPIT with their Viaskin Peanut therapy.Click to visit sponsor 

During a phase 3 clinical trial known as “EPITOPE”, researchers sought to determine the safety and efficacy of EPIT in children ages 3 and younger. Candidate children were administered a double-blind, placebo-controlled food challenge (DBPCFC) to determine whether they could tolerate a 300mg eliciting dose or less of peanut protein equivalent to 1½ peanuts. Those that could not were randomly assigned to cohorts to receive either a peanut patch for 12 months of daily treatment (244 children) or a placebo patch (118 children). Safety was evaluated based on treatment-emergent adverse events (TEAEs).

Of the 362 children (median age: 2.5 years; 68.8% male), 84.8% were able to complete treatment. About 67% of children in the active peanut patch cohort and 33.5% in the placebo patch cohort achieved the primary efficacy endpoint of tolerating 300mg of peanut protein. In addition, 64.2% of children who received the active patch and 29.6% who received the placebo had a peanut protein eliciting dose of 1000mg or greater.Click to visit sponsor 

Most TEAEs were mild or moderate reactions confined to the application site. Serious TEAEs occurred in 8.6% of children using the peanut patch and in 2.5% using the placebo patch. Among the children using the peanut patch, 4 (1.6%) suffered treatment-related anaphylaxis and 8 (3.3%) discontinued participation due to a TEAE.

The researchers concluded:

Twelve months of epicutaneous immunotherapy with a patch containing 250µg peanut protein was associated with a statistically significant response vs placebo among peanut-allergic children aged 1-3 years.